Checked July 13, 2026. There are three prices for Zepbound (tirzepatide), and which one applies to you depends entirely on how you buy it. The list price is about $1,086.37 for a 28-day supply of single-dose pens — the same at every strength. If you have commercial insurance that actually covers Zepbound, Lilly's savings card can bring a fill down to as low as $25, subject to per-fill and annual savings caps that decide whether you actually land on $25. If you pay cash through Lilly's self-pay pharmacy channel, the price is $299 to $449 a month depending on dose and how quickly you refill. Medicare and Medicaid are excluded from the savings card — but that is not the end of the story, and the sleep-apnea approval is the reason why.
The three numbers, side by side
| Route | What you pay per month | Who it's for |
|---|---|---|
| Retail pharmacy, no coverage, no program | ~$1,086 (list price for a 28-day box of four single-dose pens) | Almost nobody should land here — every other row is cheaper |
| Commercial insurance + Zepbound Savings Card | As low as $25 per fill — but the card pays at most $100 toward a 1-month fill ($200 for 2 months, $300 for 3 months), up to $1,300 a calendar year | Commercially insured people whose plan covers Zepbound for their indication |
| Self-pay (LillyDirect Pharmacy and participating pharmacies) | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with an on-time refill) | Cash payers: uninsured, or insured but not covered for this drug |
| Self-pay, higher doses without the on-time refill | $499 (7.5 mg), $699 (10, 12.5 and 15 mg) | The price you fall back to if a refill lapses past 45 days |
| Medicare GLP-1 Bridge (from July 1, 2026) | $50 per month, flat, regardless of dose | Part D enrollees who meet CMS's BMI and diagnosis criteria — see below |
The $25 and $299 numbers are not competing offers for the same person. They are two different doors, and you can only walk through one of them.
Vials, KwikPens, single-dose pens: the distinction most people miss
Zepbound comes in three physical formats, and the format tracks the price more than the dose does.
- Single-dose pens — the four-pen carton dispensed at a normal retail pharmacy. This is what carries the ~$1,086 list price, and this is the one your insurance pays a negotiated slice of.
- Single-dose vials — you draw the dose into a syringe yourself. These were introduced specifically as the cheap cash-pay format.
- The single-patient-use KwikPen — a multi-dose pen sold through the same self-pay channel.
Here is the current, honest picture, which contradicts a lot of older articles still on the internet: as of July 13, 2026 the vial is no longer uniquely cheap. Lilly's self-pay pricing now starts at the same $299 (2.5 mg) and $399 (5 mg) for both the vial and the KwikPen, and its Self Pay Journey Program applies a $449 price to the 7.5 mg through 15 mg strengths in either format, applied automatically on a first purchase of those strengths from February 23, 2026. Lilly's published terms attach a condition: refill within 45 days of your previous delivery, or the regular self-pay prices apply — $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg. Lilly's savings and self-pay programs, as published, are stated to expire on December 31, 2026, which means every number on this page has an expiry date attached to it.
So the real lever is not vial-versus-pen. The lever is channel. Buying through the manufacturer's self-pay pharmacy — including retail pick-up options that carry the direct-to-consumer price — costs a few hundred dollars. Buying the same molecule as a retail-pharmacy single-dose pen without coverage costs roughly a thousand. Nothing about the medicine changes.
What the label says about dose (and what it does not say)
Because self-pay price is tied to strength, people naturally start doing arithmetic. Before you do: the label is a reference, not an instruction, and your prescriber sets your dose.
The FDA label publishes a starting dosage of 2.5 mg once weekly for four weeks, which it states is for initiation only and is not a maintenance dose, with increases in 2.5 mg increments no sooner than every four weeks. Published maintenance dosages are 5 mg, 10 mg or 15 mg once weekly for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea; the maximum is 15 mg weekly. That is the public fact. It is not a plan for you.
Do not self-adjust to save money. Do not stretch the interval between doses, do not split a vial, and do not double up after a missed dose. Only your prescriber decides what dose you take and when it changes. If cost is what is driving the question, say that out loud to your prescriber — the fix is a different purchase route or a different drug, not a different needle. Our GLP-1 dosing schedule explainer covers what the label publishes in more detail, on the same terms.
The savings card: who it works for, who it locks out
Lilly's Zepbound Savings Card is a commercial-insurance product. If your commercial plan covers Zepbound, the card is stated to bring a 1-, 2- or 3-month fill down to as low as $25 — and here is the part almost nobody reads before budgeting. As of July 13, 2026, Lilly's published terms cap what the card pays: a maximum of $100 in savings on a 1-month fill, $200 on a 2-month fill, $300 on a 3-month fill, and a separate maximum of $1,300 per calendar year, across up to 13 fills. So $25 is the floor, not the promise: if your plan's copay is $180, the card takes $100 off and you pay $80, not $25. And a card that saves $1,300 and then stops is a card that runs out partway through the year for many people. Read the current terms before you plan a budget around it.
The exclusion is blunt and it is not negotiable. Lilly's terms state the card cannot be used by anyone enrolled in any state, federal or government-funded healthcare program — Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, TRICARE, VA, DoD. This is a federal anti-kickback rule, not a Lilly preference, and it applies across essentially every brand-drug copay card in the US. If you are on Medicare, the card is not an option and no one at the pharmacy can make it one.
What is still open to you: the self-pay cash price. Lilly's self-pay terms require you to be 18 or older, a US or Puerto Rico resident, and not seeking insurance reimbursement for the cost. Paying cash while holding Medicare is a real route people use — but confirm your own eligibility against the current terms rather than against a forum post.
Medicare, Medicaid, and the sleep-apnea twist
Medicare Part D has historically excluded drugs used for weight loss by statute. Two things have changed that answer, and they matter to different people.
1. Zepbound is approved for obstructive sleep apnea. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for OSA — based on the SURMOUNT-OSA trials, in which it cut breathing interruptions by roughly 25–29 events per hour versus about 5 on placebo. That approval created a medically accepted indication that is not "weight loss." A Part D plan that is forbidden from covering an obesity drug may be permitted to cover the same drug for OSA. This is the single most under-covered fact on this topic: if you snore, wake unrefreshed, or have been told you stop breathing at night, a sleep study is not just a health question — it can be the difference between $1,086 and a copay. Sleep apnea in women is routinely missed, because it often presents as fatigue, insomnia and brain fog rather than the classic loud-snoring picture.
2. The Medicare GLP-1 Bridge. From July 1, 2026 through December 31, 2027, CMS is running a demonstration that offers eligible Part D enrollees certain GLP-1 medicines for a flat $50 a month, which does not rise with dose. For Zepbound, the eligible formulation is the KwikPen. Eligibility runs on BMI tiers plus diagnoses: BMI 35 or higher on its own; BMI 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease; or BMI 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease. Note the wrinkle: CMS states that people whose GLP-1 is prescribed for an indication Part D can already cover — moderate-to-severe OSA, type 2 diabetes, MASH — are not eligible for the Bridge, precisely because their own plan can pay for it. Also note what the $50 does not do — CMS states it does not count toward your Part D deductible or your annual out-of-pocket cap ($2,100 in 2026).
Medicaid is state-by-state. Some states cover anti-obesity medication, many do not, and a separate CMS model beginning in 2026 lets participating states adopt standardized coverage criteria. Your state's preferred drug list is the only document that answers this.
Routes to a lower price, ranked by what they actually save
| Route | Realistic monthly cost | The catch |
|---|---|---|
| Get it covered, then use the savings card | As low as $25 per fill | Commercial insurance only; the card pays at most $100 per 1-month fill and $1,300 a year; usually needs prior authorization and documented BMI/comorbidity |
| Coverage via the OSA indication | Your plan's specialty copay | Requires a sleep study and a documented moderate-to-severe OSA diagnosis; not everyone has OSA |
| Medicare GLP-1 Bridge | $50 flat | Part D only, defined BMI/diagnosis tiers, KwikPen formulation, ends Dec 31, 2027, doesn't count toward the deductible or the out-of-pocket cap |
| Lilly self-pay (vial or KwikPen) | $299–$449 | Cash only, no insurance reimbursement; higher doses need a refill within 45 days or the price reverts to $499–$699 |
| Employer or plan appeal after a denial | Varies | Slow, but a formulary exception is the only thing that changes a "not covered" into a copay |
| Switch to a different covered GLP-1 | Varies | A clinical decision, not a shopping decision — see Zepbound vs Wegovy |
Two things we will not tell you to do. We will not coach you to describe your situation to an insurer in any way other than accurately — a claim built on a misstatement can be clawed back, and it puts your prescriber's licence in the room. And we will not tell you to use or avoid compounded tirzepatide: the FDA declared the tirzepatide shortage resolved in December 2024, which removed the legal basis for large-scale compounding of copies, and compounded versions are not FDA-approved products — the FDA does not review them for safety, effectiveness or manufacturing quality. If a telehealth site is offering "generic tirzepatide," that is a question to take to a clinician and to your state pharmacy board, not a bargain to act on.
How to evaluate a telehealth or online route
Plenty of services will happily sell you access. Judge them on four things: Do they employ a licensed prescriber who will actually review your history, or is it a form and a rubber stamp? Do they dispense FDA-approved Zepbound, or a compounded product — and do they say so in plain words before you pay? Is the monthly fee separate from the drug price, and what happens to it if you stop? Will they send documentation your regular doctor can use? Our guides to choosing GLP-1 care online and the cost and coverage estimator are built for exactly this comparison.
Disclosure: VidaBeacon may earn a commission if you use some of the links on this site to reach a care provider or product. It does not change what we write, and no company paid for placement in this article. Prices here come from the manufacturer's and CMS's own published pages, checked July 13, 2026.
When to talk to your prescriber
Book a conversation — do not improvise — if any of these apply:
- Cost is about to make you stop or ration. Say it plainly. There is often a route (a different formulation, the self-pay channel, an appeal) that your prescriber knows and you don't.
- You were denied. Ask for the exact denial reason in writing, the plan's coverage criteria for tirzepatide, and whether a formulary exception or prior authorization with your documented comorbidities is worth filing.
- You snore, gasp, or wake exhausted. Ask whether a sleep study is warranted. It can change both your health and your coverage answer.
- You have a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, gallbladder disease, or you are pregnant or planning pregnancy — these are label-level safety conversations, not price conversations.
- Side effects are making you consider changing your own dose. Bring it to the prescriber instead. See tirzepatide side effects for what's common and what is not.
The exact question to ask your plan, verbatim: "Is tirzepatide (Zepbound) on my formulary, at what tier, for which indications, and what are the prior-authorization criteria — including whether coverage differs for obstructive sleep apnea?" Get the answer with a reference number. Your plan decides this, we cannot know it from here, and that sentence is how you make them tell you.
For the wider picture of how these drugs work and what to expect from them, start with GLP-1 medications explained and tirzepatide: Mounjaro vs Zepbound. More on midlife metabolism in weight and metabolism.
